Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-5619 augmentation therapy for negative symptoms and cognition in outpatients with schizophrenia
2011-005138-21Phase 2Completed
- Sponsor
- Targacept
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing TC-5619 augmentation arm with Placebo augmentation arm (2 arms). Primary endpoint: Primary efficacy endpoint. Started Apr 2012; status: completed.
02
Drugs
bradanicline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2011-005138-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005138-21.